|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | **Estimate** | **Standard error** | **95% Confidence interval** | **Standardized Estimate** | **df** | **Minimum** | **Maximum** | **t** | **Pr > |t|** |
| **Intercept** | 14.3664 | 10.0271 | -5.2871 | 34.0199 |   | 38317 | 10.9710 | 16.8212 | 1.43 | 0.1519 |
| **ASMI** | -0.3599 | 0.4483 | -1.2385 | 0.5188 | -0.1021 | 141783 | -0.4461 | -0.2440 | -0.80 | 0.4221 |
| **Age** | -0.0617 | 0.1100 | -0.2774 | 0.1540 | -0.0644 | 4731.4 | -0.1088 | -0.0168 | -0.56 | 0.5751 |
| **Self-reported sex** | -1.3351 | 1.5273 | -4.3285 | 1.6583 | -0.1053 | 223512 | -1.6547 | -1.1258 | -0.87 | 0.3820 |
| **Baseline MADRS, severe** | -0.2691 | 1.6344 | -3.4727 | 2.9345 | -0.0214 | 19423 | -0.7349 | 0.2544 | -0.16 | 0.8692 |
| **CIRS\*** | -0.3657 | 0.1746 | -0.7081 | -0.0234 | -0.2717 | 2302.9 | -0.4531 | -0.2883 | -2.10 | 0.0363\* |
| **Cardiovascular disease** | 1.5501 | 1.8410 | -2.0584 | 5.1585 | 0.0926 | 29253 | 0.8986 | 1.9994 | 0.84 | 0.3998 |
| **Arrhythmia** | 2.0836 | 3.1567 | -4.1036 | 8.2708 | 0.0766 | 75489 | 1.3336 | 2.8412 | 0.66 | 0.5092 |
| **Previously married\*** | -4.8281 | 2.0693 | -8.8847 | -0.7716 | -0.3610 | 5931.2 | -5.6584 | -4.1280 | -2.33 | 0.0197\* |
| **Currently married\*** | -4.0788 | 1.8601 | -7.7246 | -0.4330 | -0.3238 | 36750 | -4.7156 | -3.5921 | -2.19 | 0.0283\* |
| **Baseline HDRS-17 score, total** | -0.2391 | 0.1909 | -0.6133 | 0.1350 | -0.1736 | 24356 | -0.3136 | -0.1947 | -1.25 | 0.2103 |
| **MOS-Physical** | 0.0159 | 0.0645 | -0.1107 | 0.1425 | 0.0312 | 2207.6 | -0.0220 | 0.0442 | 0.25 | 0.8056 |
| **Total cholesterol, medium** | -2.9768 | 1.9836 | -6.8652 | 0.9116 | -0.2228 | 7566.5 | -3.7448 | -2.0993 | -1.50 | 0.1335 |
| **Total cholesterol, high** | 3.6199 | 4.5108 | -5.2287 | 12.4684 | 0.1338 | 1430.3 | 0.7154 | 6.2384 | 0.80 | 0.4224 |
| **LDL cholesterol, medium\*** | 3.7344 | 1.8542 | 0.0990 | 7.3699 | 0.2961 | 3701.6 | 2.5748 | 4.4671 | 2.01 | 0.0441\* |
| **LDL cholesterol, high** | -0.9826 | 4.0947 | -9.0125 | 7.0473 | -0.0427 | 2222.3 | -3.2883 | 0.7627 | -0.24 | 0.8104 |
| **Length of current episode** | -0.6855 | 0.5514 | -1.7667 | 0.3957 | -0.1469 | 3350.4 | -0.8625 | -0.3433 | -1.24 | 0.2139 |

Supplementary Table 2a. Summary of multivariate model for HDRS-17 score change during the randomized treatment phase in participants receiving aripiprazole

ASMI: Appendicular skeletal mass (ASM) index (ASM divided by height2)

MADRS: Montgomery-Åsberg Depression Rating Scale

CIRS: Cumulative Illness Rating Scale

HDRS: Hamilton Depression Rating Scale

MOS: Medical Outcomes Study questionnaire

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | **Estimate** | **Standard error** | **95% Confidence interval** | **Standardized Estimate** | **df** | **Minimum** | **Maximum** | **t** | **Pr > |t|** |
| **Intercept** | -4.5346 | 13.0154 | -30.0589 | 20.9896 |   | 2110.6 | -10.7639 | 4.8192 | -0.35 | 0.7276 |
| **ASMI** | -0.1194 | 0.7337 | -1.5604 | 1.3215 | -0.0231 | 576.72 | -0.8730 | 0.2761 | -0.16 | 0.8707 |
| **Age** | 0.0910 | 0.1276 | -0.1591 | 0.3410 | 0.0802 | 7301.2 | 0.0447 | 0.1397 | 0.71 | 0.4759 |
| **Self-reported sex** | 1.1560 | 1.9619 | -2.6917 | 5.0036 | 0.0912 | 1901.6 | 0.2275 | 2.4973 | 0.59 | 0.5558 |
| **Baseline MADRS, severe** | -0.3746 | 1.8201 | -3.9442 | 3.1949 | -0.0301 | 1939.8 | -1.4013 | 0.8214 | -0.21 | 0.8369 |
| **CIRS** | -0.0724 | 0.1916 | -0.4483 | 0.3035 | -0.0480 | 1055.3 | -0.1832 | 0.0810 | -0.38 | 0.7056 |
| **Cardiovascular disease** | -3.1426 | 2.1922 | -7.4398 | 1.1546 | -0.1817 | 9045.3 | -4.0800 | -2.1793 | -1.43 | 0.1517 |
| **Arrhythmia** | -2.7162 | 1.9791 | -6.5954 | 1.1631 | -0.1521 | 18656 | -3.3094 | -1.9882 | -1.37 | 0.1700 |
| **Previously married** | -1.4869 | 2.3540 | -6.1022 | 3.1283 | -0.1155 | 3974.3 | -2.8543 | -0.5591 | -0.63 | 0.5276 |
| **Currently married** | -3.7538 | 2.2577 | -8.1808 | 0.6732 | -0.2989 | 2596.9 | -4.8016 | -2.7511 | -1.66 | 0.0965 |
| **Baseline HDRS-17 score, total** | -0.1509 | 0.2049 | -0.5525 | 0.2508 | -0.1093 | 3313.6 | -0.2614 | -0.0830 | -0.74 | 0.4614 |
| **MOS-Physical** | 0.0629 | 0.0677 | -0.0698 | 0.1957 | 0.1138 | 1100.7 | 0.0194 | 0.1076 | 0.93 | 0.3525 |
| **Total cholesterol, medium** | 2.6220 | 1.8327 | -0.9716 | 6.2157 | 0.1918 | 2887.3 | 1.3832 | 3.8943 | 1.43 | 0.1526 |
| **Total cholesterol, high** | 5.5023 | 3.9850 | -2.3801 | 13.3848 | 0.2968 | 132.5 | 0.0808 | 9.3978 | 1.38 | 0.1697 |
| **LDL cholesterol, medium** | 1.1363 | 1.7671 | -2.3284 | 4.6011 | 0.0900 | 3126.9 | -0.2819 | 1.9642 | 0.64 | 0.5202 |
| **LDL cholesterol, high** | -4.1494 | 3.7622 | -11.5623 | 3.2634 | -0.2159 | 230.24 | -7.3302 | 0.2456 | -1.10 | 0.2712 |
| **Length of current episode** | -0.5363 | 0.5123 | -1.5405 | 0.4679 | -0.1202 | 25397 | -0.6836 | -0.3606 | -1.05 | 0.2952 |

Supplementary Table 2b. Summary of multivariate model for HDRS-17 score change during the randomized treatment phase in participants receiving placebo

ASMI: Appendicular skeletal mass (ASM) index (ASM divided by height2)

MADRS: Montgomery-Åsberg Depression Rating Scale.

CIRS: Cumulative Illness Rating Scale.

HDRS: Hamilton Depression Rating Scale.

MOS: Medical Outcomes Study questionnaire.